Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the ...
Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with ...
Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...
Biogen Inc. (NASDAQ:BIIB – Get Free Report) was the recipient of unusually large options trading on Monday. Stock traders purchased 32,455 put options on the company. This represents an increase of ...
Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...
Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...
It was five years ago today that then-Gov. Charlie Baker declared a State of Emergency in Massachusetts due to the rapidly ...
Markets are tanking on tariff fears, inflationary concerns and now fears of recession. “Given this is so uncertain and that ...
Biogen, Eisai’s Leqembi Suffers Overseas Setbacks as UK Denies Coverage, Australia Denies Approval
Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...
Unusual total active option classes on open include: Biogen ( BIIB ), Checkpoint Therapeutics ( CKPT ), Veren Inc. ( VRN ), Redfin ( RDFN ), Novo Nordisk ( NVO ), Dow Chemical (DOW), Kraft Heinz ( KHC ...
The results of the Intuition Brain Health study – sponsored by Biogen and supported by Apple – show the feasibility of using ...
The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback